Dedifferentiated, programmable stem cells of monocytic origin, and their production and use

Abstract

The invention relates to the production of adult dedifferentiated, programmable stem cells from human monocytes by cultivation of monocytes in a culture medium which contains M-CSF and IL-3. The invention further relates to pharmaceutical preparations, which contain the dedifferentiated, programmable stem cells and the use of these stem cells for the production of target cells and target tissue.

1 - 29 . (canceled)  
   
   
       30 . A method of producing a target cell from a dedifferentiated, programmable cell of human monocytic origin comprising: 
 a) obtaining a desired target cell from a target tissue;    b) incubating said desired target cell in a suitable culture medium; and    c) providing supernatant from said culture medium after incubation with said desired target cell to dedifferentiated, programmable stem cells of human monocytic origin, wherein said cells express a CD14 antigen and a CD90 antigen to differentiate said cell of human monocytic origin into a target cell.    
   
   
       31 . The method according to  claim 30 , wherein said cell of human monocytic origin is differentiated into a adipocyte, a neuron, a glia cell, an endothelial cell, a keratinocyte, a hepatocyte or an islet cell.  
   
   
       32 - 34 . (canceled)  
   
   
       35 . The method according to  claim 30 , wherein said target cell also expresses a CD14 antigen.  
   
   
       36 . The method according to  claim 30 , wherein said dedifferentiated, programmable cell of human monocytic origin expresses a CD123 antigen.  
   
   
       37 . A method of producing a target cell from a dedifferentiated, programmable cell of human monocytic origin comprising: 
 a) providing a differentiation medium for differentiation of said dedifferentiated, programmable cell of human monocytic origin, wherein said dedifferentiated, programmable cell expresses a CD14 antigen and a CD90 antigen; and    b) differentiating said dedifferentiated, programmable cell of human monocytic origin into a target cell that express a target cell protein.    
   
   
       38 . The method according to  claim 37 , wherein said target cell also expresses a CD14 antigen.  
   
   
       39 . The method according to  claim 37 , wherein said differentiation medium comprises a factor selected from a group consisting of epidermal growth factor (EGF), hepatocyte growth factor, keratinocyte growth factor, and combinations thereof.  
   
   
       40 . The method according to  claim 37 , wherein said target cell protein is albumin.  
   
   
       41 . The method according to  claim 37 , wherein said target cell is transfected with a gene.  
   
   
       42 . The method according to  claim 37 , wherein said dedifferentiated, programmable cell of human monocytic origin is differentiated into an adipocyte, a neuron, a glia cell, an endothelial cell, a keratinocyte, a hepatocyte or an islet cell.  
   
   
       43 . A method of producing a target cell from a dedifferentiated, programmable cell of human monocytic origin comprising: 
 a) providing a differentiation medium for differentiation of said dedifferentiated, programmable cell of human monocytic origin, wherein said dedifferentiated, programmable cell expresses a CD14 antigen and a CD90 antigen; and    b) differentiating said dedifferentiated, programmable cell of human monocytic origin into said target cell that expresses a target cell protein.    
   
   
       44 . A method of producing a target cell from a dedifferentiated, programmable cell of human monocytic origin comprising administering into a body said dedifferentiated, programmable cell of human monocytic origin, wherein said dedifferentiated, programmable cell of human monocytic origin expresses a CD14 antigen and a CD90 antigen.  
   
   
       45 . The method of  claim 44 , wherein said administering is injecting, implanting, or infusing a dedifferentiated, programmable cell of human monocytic origin.  
   
   
       46 . The method of  claim 44 , wherein said dedifferentiated, programmable cell of human monocytic origin is in phosphate buffered saline (PBS).  
   
   
       47 . A method of producing a target cell from a dedifferentiated, programmable cell of human monocytic origin comprising: 
 a) applying to a material said dedifferentiated, programmable cell of human monocytic origin, wherein said dedifferentiated, programmable cell of human monocytic origin expresses a CD14 antigen and a CD90 antigen; and    b) administering said material into a body.    
   
   
       48 . The method of  claim 47 , wherein said administering is injecting, implanting, or infusing.  
   
   
       49 . The method of  claim 47 , wherein said material is selected from the group consisting of a cardiac valve, a vessel prosthesis, a bone prosthesis, a joint prosthesis, a bag, a chamber, and a biodegradable matrix.  
   
   
       50 . A method of treating a patient with a target cell from a dedifferentiated, programmable cell of human monocytic origin comprising: 
 a) providing a differentiation medium for differentiation of said dedifferentiated, programmable cell of human monocytic origin, wherein said dedifferentiated, programmable cell expresses a CD14 antigen and a CD90 antigen; and    b) differentiating said dedifferentiated, programmable cell of human monocytic origin into said target cell that expresses a target cell protein;    c) administering said target cell to a patient.    
   
   
       51 . The method of  claim 50 , wherein said administering is injecting, implanting, or infusing.  
   
   
       52 . The method of  claim 50 , wherein said target cell is administered on a material selected from the group consisting of a cardiac valve, a vessel prosthesis, a bone prosthesis, a joint prosthesis, a bag, a chamber, and a biodegradable matrix.  
   
   
       53 . The method of  claim 50 , wherein said patient has a disease selected from the group consisting of cirrhosis of the liver, pancreatic insufficiency, acute or chronic kidney failure, hormonal under-functioning, cardiac infarction, pulmonary embolism, stroke and skin damage.